member
Steevanson BAYER
CEO, LAMPRay Diagnostics Limited
I earned my PhD in Chemistry at the Hong Kong University of Science and Technology (HKUST), where I explored the intersection of nanomaterials, biosensors, and microfluidics to advance next-generation point-of-care diagnostics. During my doctoral journey, I founded my first startup through HKUST’s Dream Builder Incubation Program (DBIP). Since then, HKUST has been an invaluable partner, fueling both scientific innovation and entrepreneurial growth.
Company Description
At LAMPRay Diagnostics, we are developing a breakthrough point-of-care platform for personalized medicine. Our journey began by tackling antimicrobial resistance (AMR), one of the most urgent healthcare challenges of our time. From there, we aim to expand into broader biomarker panels for longevity and precision health.
Our solution is powered by a patented microfluidic chip integrated with an AI-enhanced analytical device, delivering fast, accurate, and affordable diagnostics. It is 3 times faster and 30 times more cost-efficient than existing systems, enabling hospitals and clinics, especially in low-resource and developing regions, to detect and manage AMR early. Our device can identify up to 8 major pathogens, including MRSA, within hours, not days.
At LAMPRay, our mission is simple yet profound: to make advanced diagnostic technology accessible to everyone, everywhere. We believe no patient should have to wait too long, travel too far, or pay too much for timely, life-saving care. We invite partners and investors to join us in combating superbugs, one drop at a time.